Deutsch English Français

Contact

EP1569646

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP1569646

EP1569646 - PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 17.09.2010 Database last updated on 24.08.2024
Most recent event Tooltip	17.09.2010	Application deemed to be withdrawn	published on 20.10.2010 [2010/42]
Applicant(s)	For all designated states GlaxoSmithKline LLC One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 / US
	[N/P]
Former [2010/09]	For all designated states GlaxoSmithKline LLC One Franklin Plaza 200 North 16th Street Philadelphia, PA 19102 / US
Former [2005/36]	For all designated states SMITHKLINE BEECHAM CORPORATION One Franklin Plaza Philadelphia, PA 19102 / US
Inventor(s)	01 / KAZMIERSKI, Wieslaw Mieczyslaw GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Par, NC 27709 / US
	02 / AQUINO, Christopher Joseph GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	03 / BIFULCO, Neil GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	04 / BOROS, Eric Eugene GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	05 / CHAUDER, Brian Andrew GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	06 / CHONG, Pek Yoke GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	07 / DUAN, Maosheng GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	08 / DEANDA, JR. Felix GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	09 / KOBLE, Cecilia Suarez GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	10 / MCLEAN, Ed Williams GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	11 / PECKHAM, Jennifer Poole GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	12 / PERKINS, Angilique C. GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 027709 / US
	13 / THOMPSON, James Benjamin GlaxoSmithKline, Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709 / US
	14 / VANDERWALL, Dana GlaxoSmithKline, Five Moore Drive, O Box 13398 Research Triangle Park, NC 27709 / US
	[2005/36]
Representative(s)	Gladwin, Amanda Rachel GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB
	[N/P]
Former [2005/36]	Gladwin, Amanda Rachel GlaxoSmithKline, Corporate Intellectual Property, CN925.1, 980 Great West Road Brentford Middlesex TW8 9GS / GB
Application number, filing date	03813419.3	12.12.2003
	[2005/36]
	WO2003US39644
Priority number, date	US20020433634P	13.12.2002 Original published format: US 433634 P
	[2005/36]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2004054974
	Date:	01.07.2004
	Language:	EN
	[2004/27]
	Type:	A2 Application without search report
	No.:	EP1569646
	Date:	07.09.2005
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 01.07.2004 takes the place of the publication of the European patent application.
	[2005/36]
Search report(s)	International search report - published on:	EP	02.09.2004
Classification	IPC:	A61K31/46, A61K31/445, C07D451/04, A61P31/18	[2005/36]
	CPC:	C07D451/04 (EP,KR,US); A61K31/46 (KR); A61P31/12 (EP); A61P31/18 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/36]
Extension states	AL	Not yet paid
	LT	06.06.2005
	LV	06.06.2005
	MK	Not yet paid
Title	German:	PIPERIDINDERVIATEALS CCR5-ANTAGONISTEN	[2005/36]
	English:	PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS	[2005/36]
	French:	ANTAGONISTES DE CCR5 UTILES COMME AGENTS THERAPEUTIQUES	[2005/36]
Entry into regional phase	06.06.2005	National basic fee paid
	06.06.2005	Designation fee(s) paid
	06.06.2005	Examination fee paid
Examination procedure	09.06.2004	Request for preliminary examination filed International Preliminary Examining Authority: EP
	06.06.2005	Examination requested [2005/36]
	11.11.2008	Despatch of a communication from the examining division (Time limit: M06)
	11.05.2009	Reply to a communication from the examining division
	12.10.2009	Despatch of a communication from the examining division (Time limit: M06)
	23.04.2010	Application deemed to be withdrawn, date of legal effect [2010/42]
	01.06.2010	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2010/42]
Fees paid	Renewal fee
	05.12.2005	Renewal fee patent year 03
	05.12.2006	Renewal fee patent year 04
	05.12.2007	Renewal fee patent year 05
	08.12.2008	Renewal fee patent year 06
	07.12.2009	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y]WO9904794 (MERCK & CO INC [US], et al) [Y] 1-61 * page 103, line 12 - line 17; claims 1,15,18,20 *;
		[Y]WO0038680 (PFIZER LTD [GB], et al) [Y] 1-61 * page 27, line 10; claims 1,2,5-20 *;
		[A]WO02079190 (SMITHKLINE BEECHAM PLC [GB], et al) [A] 1-61 * page 12, line 1 - line 3; claim 1; table 1 *;
		[X]WO9825605 (MERCK & CO INC [US], et al) [X] 1-61 * page 61, line 5 - line 11; claims 1,11 * * page 16 - page 34 *;
		[X]US5340822 (EMONDS-ALT XAVIER [FR], et al) [X] 1-23,25-28,52-54,59,60 * column 1, line 11 - line 24; examples 22-24; claim 1 *;
		[X]BE601228 (JANSSEN PAUL ADRIAAN JAN) [X] 1-23,25-28,54 * page 2, line 23 - line 27; claim 1 * * page 9, line 10 - page 28, line 10 *;
		[X]US2773870 (BILL ELPERN) [X] 1-23,25-28,54 * column 1, line 20 - line 61 * * examples *;
		[X]US3539580 (HERMANS HUBERT KAREL FRANS, et al) [X] 1-23,25-28,54 * column 1, line 13 - line 15; claims 1,5-7 * * table *;
		[X]US3334106 (BIEL JOHN H) [X] 1-23,25-28,54 * the whole document *;
		[X]US2248018 (OTTO EISLEB) [X] 1,25-28,54 * column 1, line 52 - line 55; examples 3,4; claim 6 *;
		[X]WO9825604 (MERCK & CO INC [US], et al) [X] 1,7-12,20,25-61 * page 30, line 26 - line 30 * * page 34, line 1 - line 22 * * page 55 - page 85; claim 1 *;
		[X]JP2002348288
		[X] - REHSE K ET AL, "Platelet aggregation inhibiting and anticoagulant effects of oligoamines, 1: N-(4-piperidinyl)methanamines", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, (1986), vol. 319, no. 319, ISSN 0365-6233, pages 505 - 515, XP001085385 [X] 1,25-28,52-54,59,60 * the whole document * DOI: http://dx.doi.org/10.1002/ardp.19863190606
		[X] - STEVENTON ET AL, "4,4-disubstituted Piperidine High-Affinity NK1 Antagonists: Structure-Activity Relationships and in Vivo Activity", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, (1998), vol. 41, no. 23, ISSN 0022-2623, pages 4623 - 4622, XP002173109 [X] 1,25-28,54 * the whole document * DOI: http://dx.doi.org/10.1021/jm980376b
		[X] - DATABASE WPI, 0, Derwent World Patents Index, vol. 2003, no. 35, Database accession no. 2003-367209, XP002283279 & JP2002348288 A 20021204 (ONO PHARM CO LTD) [X] 1,7-12,20,25-61 * abstract *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p